This site is intended for healthcare professionals
COMT inhibition in Parkinson’s Disease Learning Zone

eLearning modules

Read time: 70 mins
Last updated:11th Nov 2020
Published:11th Aug 2020
Understand why patients usually require higher and more frequent dosing of levodopa or the addition of other therapies such as COMT inhibitors as PD progresses.

Find out when levodopa therapy may be initiated and discover how catechol-O-methyltransferase (COMT) inhibitors may be used in conjunction with levodopa to help control motor symptoms in patients with Parkinson’s disease (PD). In these interactive eLearning modules, the expert faculty address important questions in the field of PD research, providing insight into the steps that can be taken to optimise patient outcomes.

Levodopa is considered the gold standard of treatment in Parkinson’s disease, but there is still some debate as to when levodopa therapy should be initiated.

Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

Diagnosing motor fluctuations in patients with Parkinson’s disease can be challenging, particularly in early-stage disease.

Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

Welcome: